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With the growing class of CFTR modulator therapy available to more patients and with increasing pregnancies in individuals with CF, there is a 
growing need to understand the effects of these agents during pregnancy. There are few reports of their continued use in the literature, although it is 
likely that this is not an uncommon occurrence. We report the uncomplicated and successful pregnancy of a woman treated with lumacaftor/
ivacaftor, as well as the clinical course of the infant during the first 9 months of life. We also report drug levels in plasma from the mother, cord 
blood, breast milk, and infant to estimate fetal and infant drug exposure.Keywords: CFTR modulators; Ivacaftor; Lumacaftor; Pregnancy1. Introduction
The advent of CFTR modulator therapy and other treatments
has significantly increased the life expectancy for individuals
with cystic fibrosis (CF) [1–4]. As a result, adults with CF are
more likely to have families than they have in the past [2].
Although the overall pregnancy rate among women with CF
age 18–44 is declining (mirroring trends in general population)
[5,6], the overall number of pregnancies is increasing due to the
increasing number adults with CF [2]. However, little is known
about CFTR modulator use in pregnant or breastfeeding
mothers, as outlined in a recent review of CF-therapies inthor.
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6/j.jcf.2018.05.009pregnant and breastfeeding women [7]. Presently, there is one
report of an uncomplicated pregnancy during ivacaftor use [8],
and one case of a woman who became pregnant after initiating
ivacaftor who discontinued the drug after her positive
pregnancy test [9]. As previously reported, pregnancy rates
decreased during phase III trials of CFTR modulators among
women with eligible genotype but increased after FDA
approval, suggesting that CFTR modulator use in pregnancy
may be underappreciated [6]. Here we report an uncomplicated
pregnancy of a woman treated with lumacaftor/ivacaftor
combination therapy and describe the clinical course of her
infant who was breastfed while her mother continued on this
therapy. Drug levels were measured in plasma from maternal
blood during and after pregnancy, cord blood after delivery,
and infant blood as well as breast milk to estimate fetal and
infant exposure.
2. Methods
2.1. Study oversight and sample collection
This study was approved by institutional review board at the
University of North Carolina at Chapel Hill, and informed
consent was obtained prior to the collection of any samples.
Maternal peripheral blood was collected pre-, peri-, and post-
partum. A sample of cord blood was obtained at delivery.
Breast foremilk samples were collected concurrently with all
post-natal maternal blood samples on an ad-hoc basis. Blood
samples were obtained from the infant whenever excess blood
could be obtained from a clinically-indicated sample.
Lumacaftor and ivacaftor concentrations in blood samples
were measured by mass spectrometry as previously described
[10]. Similar methods were employed for breast milk samples:
firstly an organic extraction was performed using methyl tert-
butyl ether followed by lyophilization and resuspension in
methanol solution and analysis with LC-MS. For validation,
maternal and infant plasma as well as breast milk samples were
spiked with known concentration of drug then processed and
analyzed as above, which yielded similar results among the
sample types. None of the collections were controlled for
maternal dosing times of lumacaftor/ivacaftor, and thus there
was limited utility to comparison of values across time points,
but mean, 25th, and 75th percentile values were calculated as
descriptors of the range. After establishing normal distribution
of maternal plasma levels for both lumacaftor and ivacaftor
using the D'Agostino-Pearson omnibus test, t-scores were
calculated from the cord blood samples to evaluate if these were
significantly different than maternal plasma values.3. Case report and results
A twenty-three-year-old woman Gravida 1 Para 1 (genotype
F508del/F508del, BMI 21.6, baseline FEV1 90% of predicted)
became pregnant while being treated with lumacaftor/ivacaftor
combination therapy. She discontinued this treatment at 13
weeks gestation at the advice of her CF provider, but her
respiratory function worsened, and she self-reinitiated treatment
after two weeks. She then established care at a new CF center
due to a family relocation. She was again counseled on the lackTable 1
Infant liver function test (LFTs) over time, with corresponding amount of dietary in
Infant age (days) 1 14 29 37
% of intake from breastmilk 100% 100% 100% 25%
Total Bilirubin (mg/dL) 2.0 1.0 1.4* 0.7
Direct Bilirubin (mg/dL) 1.10 0.50 0.70* 0.30
Aspartate aminotransferase (AST, U/L) 76 28 113* 33
Alanine transaminase (ALT, U/L) 24 16 17 22
Alkaline Phosphatase (U/L) 105 259 375* 266
Bold values marked with * indicate values above the lab's reference range.
† Denotes concurrent maternal treatment with levofloxacin and sulfamethoxazole/of evidence regarding the use of combination CFTR modulator
treatment in pregnancy, and she made the informed decision to
remain on therapy for the duration of her pregnancy. Her
obstetric care was provided by the maternal-fetal medicine
program at the same institution as her CF center. The patient
made a similar informed decision to breastfeed her infant
following a pre-natal consultation with the breastfeeding
medicine program as well as her pediatrician who agreed to
provide monitoring following delivery. At 38 weeks 6 days
gestation, she delivered a healthy, 2850 g baby girl by
spontaneous vaginal delivery after an uncomplicated labor.
Formal ophthalmologic evaluation of the baby was normal.
Liver function testing at 33 h was significant only for a direct
bilirubin of 1.10 mg/dL, and both mother and baby were
discharged home after 36 h.
Given the known risk of hepatic dysfunction with
lumacaftor/ivacaftor, the infant's liver function was carefully
monitored over time (Table 1). Based on the elevated aspartate
aminotransferase and total bilirubin at day 29, the patient was
advised to switch to formula for infant feeding, supplementing
one feeding in four with breast milk to maintain supply. With
normalization of these values at day 37, she increased her
breastfeeding to 50%. The infant also had follow-up ophthal-
mologic evaluations at 37 and 184 days of age, which were
normal. Her LFTs remained normal at 59 days, and she
resumed full breast-feeding. At her 90-day appointment, the
infant was well, and was meeting all of her developmental
milestones, with near-normal LFTs. At 135 days, the infant
was again noted to have LFT abnormalities, however, the
patient's mother was being treated with levofloxacin and
sulfamethoxazole/trimethoprim at that time. Again, formula
supplementation was used for 50% of feeds while on
antibiotics, after which formula supplementation ceased.
However, around this time, solid food was introduced to the
infant corresponding with a steady reduction in breastfeeding.
At 154 days, the LFT abnormalities had resolved, and
remained normal until the infant had almost completely been
weaned from breastfeeding by 267 days.
Concentrations of lumacaftor and ivacaftor in maternal
plasma, cord blood, breast milk, and infant plasma are shown
over time in Fig. 1. The mean lumacaftor concentration in
maternal plasma was 8.07 μM (25th: 5.15, 75th: 12.00), while
the average concentration of ivacaftor was 3.18 μM (25th:take from breastmilk at the time the samples were obtained.
59 76 94 135 † 154 184 267
50% 100% 100% 100% 75% 50% b25%
0.7 0.9 0.8 0.9 0.4 0.5 b0.1
0.40 0.40 0.40 0.80* b0.10 0.50 b0.10
42 48 51 77* 53 48 47
35 46 48 46 54 39 31
204 216 222 192 186 153 206
trimethoprim.









































Fig. 1. Plasma and breast milk levels (log scale) of A: lumacaftor and B: ivacaftor over time. Sample collection was not timed in relation to maternal dosing of
medication, which may account for some variability. Drug levels in plasma obtained from umbilical cord blood (diamonds) were comparable to levels obtained from
plasma from peripheral maternal blood (circles plotted with solid lines). Infant levels of lumacaftor at day of life 1 were elevated, likely reflecting higher pre-natal
values, although this effect was not seen with ivacaftor. After 135 days of life, breastmilk intake declined and was approximately 50% at day 184. Ivacaftor was not
detected in the infant plasma at this time point.0.99, 75th: 5.40). The concentration of lumacaftor in cord
blood (18.09 μM) was significantly higher than the maternal
plasma concentration over the study period (p = 0.02), while
the concentration of ivacaftor in cord blood (0.81 μM) was not
different than maternal plasma (p = 0.48). Both lumacaftor and
ivacaftor could be detected in breast milk (average concentra-
tions 0.06 and 0.09 μM). Average infant plasma concentrations
(excepting day 1 when values were more reflective of placental
transfer) were 0.20 and 0.01 μM respectively, with an average
corresponding fraction of maternal plasma levels of 2.7% and
0.5% respectively. The final infant plasma level of ivacaftor
was not detected, but infant breastmilk intake was lower at this
time point than during previously assessed values.
4. Discussion
We present here a case report of a woman with cystic
fibrosis delivering a healthy, term infant while remaining on
combination lumacaftor/ivacaftor therapy for the duration of
her pregnancy. She continued on therapy and was able to
breastfeed her child beyond six months, although with
some reductions due to transient abnormalities in liver function
tests.
The reported half-lives for lumacaftor and ivacaftor (when
co-administered) are approximately 26 and 9 h respectively,
and both drugs are reported to be approximately 99% proteinbound to plasma proteins [11]. Their apparent clearances are
2.38 and 25.1 L/h respectively for patients with CF, though
these pharmacokinetic parameters have not been tested in
pregnant women. Lumacaftor metabolism occurs principally by
oxidation and glucuronidation, although it is primarily excreted
unchanged into feces, while ivacaftor is readily metabolized by
CYP3A into active metabolites M1 and M6 [11]. Our findings
suggest that both lumacaftor and ivacaftor readily traverse the
placenta, and it is highly likely that the infant experienced
therapeutic levels of these drugs in utero. Indeed, lumacaftor
concentration in the cord plasma sample was higher than in
maternal plasma concentrations. It is possible that lumacaftor
accumulates in the continually exposed placenta or fetus,
particularly since lumacaftor is not readily metabolized. The
consequences of such exposure are unknown, although neither
drug had significant teratogenic effects in animal studies [11].
Both drugs appeared to pass into breast milk at low levels, but
enough to maintain detectable levels in infant plasma. Our data
suggest that exposure from breastfeeding is small, but of
unclear consequence. There were some mild fluctuations
observed in the infant's LFTs, but these may be attributed to
other causes (normal early-life variation observed at day 29,
and antibiotic exposure at day 135). The decision to curtail
breastfeeding was made out of an abundance of caution.
This study is limited by including only one mother-infant
dyad, and results cannot be extrapolated to the entire CF
population. Furthermore, the drug measurement method did not
include known active metabolites of ivacaftor and may have
underestimated drug exposure. It is also possible that plasma
drug concentrations do not adequately assess drug exposure,
since both lumacaftor and ivacaftor can accumulate intracellu-
larly [10]. Additionally, our methods for sample analysis in
breast milk had limited validation, and it is possible that matrix
effects may have distorted our measured concentration in this
body fluid. However, the scope of this work is more qualitative,
reporting estimates of drug exposure, rather than a fully
quantitative analysis. The findings pertaining to ivacaftor
reported here are more likely to be relevant to future CFTR
modulator treatments, as recent and planned studies with
Vertex compounds use tezacaftor in lieu of lumacaftor since the
former yielded similar clinical benefits and fewer reported side
effects and drug interactions compared to the latter in their
respective clinical trials [4,12,13]. With individuals affected by
CF living longer, and up to 85% having the potential to be
treated with highly active modulators in the foreseeable future,
modulator use in pregnancy is an important consideration,
necessitating additional study to better guide patients and
practitioners. A recent review of CF therapies in pregnancy
recommended avoiding lumacaftor and ivacaftor in both
pregnancy and breastfeeding due to lack of data [7]. This
single report of successful delivery and breastfeeding does not
provide sufficient data to support an alternative conclusion, and
further highlights the vital role of including pregnancy
information in registry data to help guide clinicians in the use
of these medications during and after pregnancy.Conflict of interest statement
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